Becton Dickinson
United States · Biotechnology, Health Care, Manufacturing
Becton Dickinson is a global medical technology company that is focused on improving drug delivery, enhancing the diagnosis of infectious diseases, and advancing drug discovery.
Key facts
- Headquarters
- United States
- Employees
- 45,895
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (BDX)
- Company page
Recent activity at Becton Dickinson
- : SEC 8-K (5.02): On July 19, 2026, Michael D. Garrison, the Executive Vice President and President of the Medical Essentials and BioPharma Systems segments at Becton, Dickinson and Company (BD), announced his intention to retire. He will continue to serve in his capacity until the end of the fiscal year to ensure a seamless transition. BD has initiated a search for a successor to lead the Medical Essentials segment. Additionally, the BioPharma Systems segment will now report directly to Thomas E. Polen, Chairman, CEO, and President of BD, as part of a strategy to streamline the company's operating model.
- : SEC 8-K (5.02): On July 19, 2026, Becton, Dickinson and Company disclosed in its 8-K filing significant changes related to its corporate governance. The filing indicates a departure of key personnel, specifically within its executive team. Although specific names and details about their positions were not provided, such changes typically suggest a strategic shift in management structure. This could impact the company's operational strategies and investor confidence moving forward, particularly in light of the ongoing evolution in the healthcare sector.
- : SEC 8-K (7.01): On May 6, 2026, Becton, Dickinson and Company placed ChloraPrep™ and PurPrep™ on ship hold due to a Warning Letter from the FDA regarding its El Paso manufacturing facility. As of May 29, 2026, the company has resumed shipments of ChloraPrep™ in the U.S. after acceptable results from additional final release testing were completed. The cessation was a precautionary measure to ensure patient safety and continuity of care. The FDA Warning Letter's implications and the product status are significant for the company's operational compliance and market supply.
- : SEC 8-K (1.01): On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a subsidiary of Becton, Dickinson and Company, issued €600,000,000 of 3.855% Notes due 2033 in an underwritten public offering. This issuance follows the indenture dated May 17, 2019, and is supported by a Sixth Supplemental Indenture dated May 20, 2026. The Notes are fully guaranteed by Becton, Dickinson and Company. The offering provides Becton Finance with the flexibility to redeem the notes at specific intervals, either at a formula-driven price or a fixed percentage of the principal. This financing is expected to support Becton Finance’s operations and balance sheet management, with strategic implications related to capital allocation and interest obligations.
- : SEC 8-K (8.01): On May 11, 2026, Becton, Dickinson and Company (BD) entered into an underwriting agreement with Barclays Bank PLC, BNP PARIBAS, Goldman Sachs & Co. LLC, Morgan Stanley & Co. International plc, and other underwriters for the sale of €600,000,000 aggregate principal amount of 3.855% Notes due 2033, fully guaranteed by BD. The offering is expected to close on or about May 20, 2026, and the proceeds will be used to repay the existing 1.208% Euro Notes due June 4, 2026, along with related accrued interest and expenses. The strategic implications include financing refinancing efforts while potentially benefiting underwriters with affiliations to prior debt instruments. This agreement reflects BD's ongoing financial management strategy to optimize its debt structure.
- : SEC 8-K (8.01): On May 11, 2026, Becton, Dickinson and Company reported significant updates regarding their outstanding debt securities. The company issued new notes including 3.519% Notes due February 8, 2031, and 3.828% Notes due June 7, 2032. These debt instruments are part of their ongoing financing operations and underline the company's strategy to manage its capital structure effectively. The details of these issues might influence investor perceptions and the company's liquidity position, highlighting their commitment to maintaining a solid financial base.
- : Becton Dickinson Appoints Vitor Roque as Chief Financial Officer
- : SEC 8-K (5.02): On April 6, 2026, Richard E. Byrd, the Executive Vice President and President of the Interventional segment at Becton, Dickinson and Company (BD), announced his intention to retire. Mr. Byrd is set to continue in his role until June 2026, and BD plans to appoint a successor before his departure. This change in leadership is significant for BD as it impacts their management structure and potentially the strategic direction of the Interventional segment.
- : SEC 8-K (8.01): On February 25, 2026, Becton, Dickinson and Company announced the early tender results for its tender offers to purchase cash totaling up to $2,000,000,000 in principal amount for various series of Senior Notes and Debentures. The tender offers include securities such as the 6.700% Senior Notes due 2026 and 7.000% Senior Debentures due 2027 among others, with specific purchase caps and conditions detailed. Holders were required to tender their securities by February 24, 2026, to qualify for the Early Tender Payment, with $36,474,000 of the $137,032,000 already tendered by that deadline. This early announcement reflects Becton, Dickinson's active financial management strategy and market engagement.
- : SEC 8-K (8.01): On February 10, 2026, Becton, Dickinson and Company announced the commencement of a series of tender offers to purchase for cash up to $1.6 billion in aggregate principal of various senior notes and debentures. The securities involved include multiple series with different due dates ranging from 2026 to 2050, representing significant financial restructuring efforts. This move indicates the company's strategic intention to manage its debt portfolio effectively, potentially reducing interest obligations over the long term. Key details include prioritized acceptance levels and aggregate purchase price caps, suggesting a calculated approach to the tender offers. The announcement was officially communicated through a press release filed as Exhibit 99.1.
Leadership
- Vitor Roque, Chief Financial Officer
Verified email and direct lines for Becton Dickinson’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Companies similar to Becton Dickinson
- IEC Medical Systems · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Boston Scientific · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Baxter International · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Alcon Silver · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Mindray · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Becton Dickinson: questions and answers
What does Becton Dickinson do?
Becton Dickinson is a global medical technology company that is focused on improving drug delivery, enhancing the diagnosis of infectious diseases, and advancing drug discovery.
Where is Becton Dickinson headquartered?
Becton Dickinson is headquartered in United States.
How many employees does Becton Dickinson have?
Becton Dickinson has about 45,895 employees.
What is the latest news on Becton Dickinson?
On Jul 22, 2026, SEC 8-K (5.02): On July 19, 2026, Michael D. Garrison, the Executive Vice President and President of the Medical Essentials and BioPharma Systems segments at Becton, Dickinson and Company (BD), announced his intention to retire. He will continue to serve in his capacity until the end of the fiscal y
Is Becton Dickinson a public company?
Yes. Becton Dickinson is publicly traded under the ticker BDX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy